Supramolecular interactions in cocrystals of benzoic acid derivatives with selective COX-2 inhibitor etoricoxib

被引:0
|
作者
Ma, Yu Heng [1 ]
Yang, Kang [1 ]
Qian, Yan Ling [1 ]
Hong, Wei Pu [1 ]
Zhang, Kai Yue [1 ]
Tao, Zhen Wei [1 ]
Meng, Hui [1 ]
Ma, Wen Jing [1 ]
机构
[1] Chuzhou Univ, Sch Mat Sci & Chem Engn, Chuzhou 239000, Anhui, Peoples R China
来源
ACTA CRYSTALLOGRAPHICA SECTION C-STRUCTURAL CHEMISTRY | 2024年 / 80卷
关键词
crystal structure; etoricoxib; cocrystal; hydrogen bonds; energy framework; benzoic acid; COX-2; inhibitor; CRYSTALEXPLORER; PROGRAM; SALTS;
D O I
10.1107/S2053229624006193
中图分类号
O6 [化学];
学科分类号
0703 ;
摘要
The structures of three 1:1 cocrystal forms of etoricoxib {ETR; systematic name: 5-chloro-2-(6-methylpyridin-3-yl)-3-[4-(methylsulfonyl)phenyl]pyridine, C18H15-ClN2O2S} have been synthesized and characterized by single-crystal X-ray diffraction; these are etoricoxib-benzoic acid (1/1), C18H15ClN2O2S center dot C7H6O2 (ETR-Bz), etoricoxib-4-fluorobenzoic acid (1/1), C18H15ClN2O2S center dot C7H5FO2 (ETR-PFB), and etoricoxib-4-nitrobenzoic acid (1/1), C18H15ClN2O2S center dot-C7H5NO4 (ETR-PNB). Powder X-ray diffraction and thermal differential scanning calorimetry-thermogravimetry (DSC-TG) techniques were also used to characterize these multicomponent systems. Due to the influence of the corresponding acids, ETR shows different conformations. Furthermore, the energetic contributions of the supramolecular motifs have been established by energy framework studies of the stabilizing interaction forces and are consistent with the thermal stability of the cocrystals.
引用
收藏
页码:366 / +
页数:25
相关论文
共 50 条
  • [21] Heme oxygenase/carbon monoxide-biliverdin pathway may be involved in the antinociceptive activity of etoricoxib, a selective COX-2 inhibitor
    Grangeiro, Niedja M. G.
    Aguiar, Jordana A.
    Chaves, Helliada V.
    Silva, Antonio A. R.
    Lima, Vilma
    Benevides, Norma M. B.
    Brito, Gerly A. C.
    da Graca, Jose R. V.
    Bezerra, Mirna M.
    PHARMACOLOGICAL REPORTS, 2011, 63 (01) : 112 - 119
  • [22] Etodolac (Lodine®): Profile of an established selective COX-2 inhibitor
    Richard A. Jones
    InflammoPharmacology, 2001, 9 (1-2) : 63 - 70
  • [24] Cyclooxygenase-2 (COX-2) in acute myocardial infarction: cellular expression and use of selective COX-2 inhibitor
    Saito, T
    Rodger, I
    Shennib, H
    Hu, F
    Tayara, L
    Giaid, A
    CANADIAN JOURNAL OF PHYSIOLOGY AND PHARMACOLOGY, 2003, 81 (02) : 114 - 119
  • [25] Selective COX-2 inhibitor celecoxib prevents experimental autoimmune encephalomyelitis through COX-2-independent pathway
    Miyamoto, Katsuichi
    Miyake, Sachiko
    Mizuno, Miho
    Oka, Nobuyuki
    Kusunoki, Susumu
    Yamamura, Takashi
    BRAIN, 2006, 129 : 1984 - 1992
  • [26] Valdecoxib: the rise and fall of a COX-2 inhibitor
    Atukorala, Inoshi
    Hunter, David J.
    EXPERT OPINION ON PHARMACOTHERAPY, 2013, 14 (08) : 1077 - 1086
  • [27] A novel genetic model of selective COX-2 inhibition: Comparison with COX-2 null mice
    Yu, Ying
    Funk, Colin D.
    PROSTAGLANDINS & OTHER LIPID MEDIATORS, 2007, 82 (1-4) : 77 - 84
  • [28] Short Synthesis of COX-2 Inhibitor Inotilone
    Al-Busafi, Saleh
    Al-Belushi, Muna
    Al-Muqbali, Khalid
    SYNTHETIC COMMUNICATIONS, 2010, 40 (07) : 1088 - 1092
  • [29] Effects of a selective COX-2 inhibitor in patients with uterine endometrial cancers
    Kiyoshi Hasegawa
    Yutaka Torii
    Risa Ishii
    Shuko Oe
    Rina Kato
    Yasuhiro Udagawa
    Archives of Gynecology and Obstetrics, 2011, 284 : 1515 - 1521
  • [30] Effects of selective Cox-2 inhibitor, rofecoxib, alone or combination with furosemide on renal functions and renal Cox-2 expression in rats
    Kose, Fatih
    Besen, Ayberk
    Paydas, Saime
    Balal, Mustafa
    Gonlusen, Gulfiliz
    Inal, Tamer
    Dogan, Ayse
    Kibar, Mustafa
    CLINICAL AND EXPERIMENTAL NEPHROLOGY, 2010, 14 (01) : 22 - 27